Competitor Analysis: Pneumococcal and Streptococcal Vaccines

Publisher: La Merie Publishing
Pages: 21
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0054
Release Date: October of 2012

200.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Pneumococcal and Streptococcal Vaccines

The present Competitive Intelligence Report about Pneumococcla and Streptococcal Vaccines provides a competitor evaluation in the field of prophylactic vaccines against infection caused by streptococcus pneumoniae (pneumococcus), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Pneumococcal disease is a leading cause of serious illness in children and adults throughout the world. The disease is caused by a common bacterium, Streptococcus pneumoniae, or pneumococcus, a gram-positive, alpha-hemolytic, bile soluble aerotolerant anaerobe, which can attack different parts of the body. When bacteria invade the lungs, they cause the most common form of community-acquired bacterial pneumonia; when bacteria invade the bloodstream, they cause bacteremia; and when they invade the covering of the brain, they cause meningitis. Pneumococci may also cause otitis media (middle ear infection) and sinusitis.

The four major commercially available pneumococcal vaccines posted worldwide sales of more than US$ 5 bln in 2011 indicating the strong interest in the healthcare sector and the vaccine industry.

The report includes a compilation of currently active projects in development of vaccines targeting pneumococcus (Streptococcus pneumoniae), Group A Streptococcus (GAS) or Group B Streptococcus (GBS) for prophylaxis of streptococcal infections. In addition, the report lists company-specific R&D pipelines of Pneumococcal and Streptococcal Vaccines. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Pneumococcal and Streptococcal Vaccines


  • Pneumococcal Vaccines
  • Group A Streptococcus (GAS) Vaccines
  • Group B Streptococcus (GBS) Vaccines & Antibodies
  • Corporate Pneumococcal and Streptococcal Vaccine R&D Pipelines
  • About La Merie


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up